The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells

British Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 703-708

  Fink, D ^a   Nebel, S ^a   Norris, P S ^b   Aebi, S ^a   Kim, H K ^a   Haas, M ^b   Howell, S B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; DNA mismatch repair; Drug resistance; Green fluorescence protein; Topoisomerase II inhibitor

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GREEN FLUORESCENT PROTEIN; MELPHALAN; PACLITAXEL; TAMOXIFEN; TIOGUANINE;

ARTICLE; BASE MISPAIRING; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031908505     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.116     Document Type: Article

References (33)

1. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R and Fishel R (1996) hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 93: 13629-13634
2. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090
3. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL and Howell SB (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res, 3: 1763-1767
4. Andrews PA, Jones JA, Varki NM and Howell SB (1990) Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2: 93-100
5. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM and Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381
6. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O and Rachmilewitz EA (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88: 4296-4303
7. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J and Meuth M (1994) Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 91: 6319-6323
8. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD and Kunkel TA (1995) Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063-6070
9. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Phamacol Toxicol 36: 191-218
10. Crameri A, Whitehorn EA, Tate E and Stemmer WPC (1996) Improved green fluorescent protein by molecular evolution using DNA snuffling. Nature Biotechnol 14: 315-319
11. de Wind N, Dekker M, Berns A, Radman M and te Riele H (1995) Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82: 321-330
12. Drummond JT, Anthoney A, Brown R and Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 56: 19645-19648
13. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93: 6443-6447
14. Fink D, Nebel S, Aebi S. Zheng H, Cenni B, Nehme A, Christen RD and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886
15. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehmé A. Christen RD. Haas M, MacLeod CL and Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841-1845
16. Fishel R and Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382-395
17. Griffin S, Branch P, Xu YZ and Karran P (1994) DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 33: 4787-4793
18. 2 cell cycle checkpoint. Cancer Res 55: 3721-3725
19. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JKV, Markowitz SD, Morin P, Kinzler KW, Vogelstein B and Dunlop MG (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93: 9049-9054
20. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P (1993) An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424-6428
21. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA and Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312
22. Kolodner R (1996) Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10: 1433-1442
23. Liu L, Markowitz S and Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1.3-bis(2-chloroethyl)nitrosourea. Cancer Res 56: 5375-5374
24. Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54: 5059-5063
25. Markowitz S, Wang J, Myeroff L, Parsons RE, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M and Willson JKV (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338
26. Mello JA, Acharya S, Fishel R and Essigmann JM (1996) The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3: 579-589
27. Morin J and Hastings (1972) Energy transfer in a bioluminescent system. J Cell Physiol 77: 313-318
28. Naviaux RK, Costanzi E, Haas, M and Verma IM (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70: 5701-5705
29. Nehmé A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JYJ, Howell SB and Christen RD (1997) Differential induction of c-Jun NH,-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 57: 3253-3257
30. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong O, Hsuan JJ and Jiricny J (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268: 1912-1914
31. Skipper HE, Schabel FM and Lloyd HH (1978) Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin Hematol 15: 207-219
32. Tomlinson IPM, Novelli MR and Bodmer WF (1996) The mutation rate and cancer. Proc NAtl Acad Sci USA 93: 14800-14803
33. Woynarowski JM, Chapman WG, Napier C and Raymond E (1997) Oxaliplatin (OxPt) effects on naked and intracellular DNA (abstract). Proc Am Assoc Cancer Res 38: 311